PDCD1 and inappropriate ADH syndrome: In contrast, PD-1 and PD-L1 inhibitors (e.g., nivolumab, pembrolizumab) are more frequently linked to SIADH-like presentations, likely due to cytokine-mediated ADH dysregulation [34,35].